Endoscopy 2025; 57(S 02): S371
DOI: 10.1055/s-0045-1805931
Abstracts | ESGE Days 2025
ePosters

Preliminary results of therapeutic response of the EUS-guided intra-tumoral implantation of Radioactive Phosphorus (32P) in 4 patients with Local Advanced Pancreatic Cancer

A Kontos
1   Agios Savvas, Cancer Hospital, Athens, Greece
,
D Kypraios
1   Agios Savvas, Cancer Hospital, Athens, Greece
,
D Dimitroulopoulos
1   Agios Savvas, Cancer Hospital, Athens, Greece
,
N Alexakis
2   Hippocration General Hospital, University of Athens, School Of Medicine, Athens, Greece
,
G Zografos
2   Hippocration General Hospital, University of Athens, School Of Medicine, Athens, Greece
,
K Toutouzas
2   Hippocration General Hospital, University of Athens, School Of Medicine, Athens, Greece
› Author Affiliations
› Further Information
Also available ateRef
 

Aims Radioactive phosphorus (32P) is an innovative therapy for locally advanced pancreatic cancer that be implanted through endoscopic ultrasound (EUS)1. The primary goal of this study is to determine the safety of the intra-tumoral implantation of radioactive phosphorus (32P) through EUS and the complications of the procedure of implantation. The secondary goals, are to determine the Local Disease Control Rate (LDCR) at 16 weeks and the effectiveness of the implantation of radioactive phosphorus by measuring Overall Survival (OS), Progression Free Survival (PFS) and Local Progression Free Survival (LPFS) [1].

Methods We currently have made the implantation in four patients with similar clinical and demographic features who suffer from locally advanced pancreatic cancer and they receive gemcitabine-based chemotherapy in combination with an intra-tumoral therapy with radioactive phosphorus (32P) through a 22 gauge FNA needle guided by EUS. The adverse events of the implantation are evaluated by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The LDCR is evaluated at 16 weeks and the alteration of Tumor Volume every two months for the first year after implantation and every three months the second year after implantation according to RECIST 1.1.

Results The four procedures of implantation were unremarkable and no complication during the procedure was noted. The patients did not have any major adverse event during the day of the procedure. Two of the patients have been followed up for 12 months and the other two for 6 months, because of different time of implantation. The LDCR, for all patients, at 16 weeks, was 100% and one of them was downstaged to resectable stage and the operation is scheduled in November of 2024 (resection rate 25%). One of the patients revealed Progression of Disease after 10 months of follow-up. The other two patients have stable disease after 12 and 6 months of follow up (different time of implantation) and therefore none of our patients have metastasis.

Conclusions Even though we currently have a small sample, the initial results look promising and we will include more patients in the immediate future so we could conduct more useful information.



Publication History

Article published online:
27 March 2025

© 2025. European Society of Gastrointestinal Endoscopy. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT.. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open 2022; 7 (1): 100356 Epub 2021 Dec 2334953400PMC8717429
    CrossrefPubMedSearch in Google Scholar